{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T09:14:47Z","timestamp":1694078087742},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2015,6,17]],"date-time":"2015-06-17T00:00:00Z","timestamp":1434499200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s11864-015-0347-3","type":"journal-article","created":{"date-parts":[[2015,6,16]],"date-time":"2015-06-16T02:39:03Z","timestamp":1434422343000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Bone Marrow Transplantation for Peripheral T-Cell Non-Hodgkins\u2019 Lymphoma in First Remission"],"prefix":"10.1007","volume":"16","author":[{"given":"Manish","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Pro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,6,17]]},"reference":[{"issue":"19","key":"347_CR1","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","volume":"117","author":"E Campo","year":"2011","unstructured":"Campo E et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019\u201332.","journal-title":"Blood"},{"issue":"1","key":"347_CR2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","volume":"107","author":"LM Morton","year":"2006","unstructured":"Morton LM et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001. Blood. 2006;107(1):265\u201376.","journal-title":"Blood"},{"issue":"1","key":"347_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.seminhematol.2013.11.009","volume":"51","author":"NM Reddy","year":"2014","unstructured":"Reddy NM, Savani BN. Management of T-cell lymphomas: overcoming challenges and choosing the best treatment. Semin Hematol. 2014;51(1):1\u20134.","journal-title":"Semin Hematol"},{"issue":"10","key":"347_CR4","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","volume":"15","author":"KJ Savage","year":"2004","unstructured":"Savage KJ et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15(10):1467\u201375.","journal-title":"Ann Oncol"},{"issue":"25","key":"347_CR5","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J et al. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124\u201330.","journal-title":"J Clin Oncol"},{"issue":"18","key":"347_CR6","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116(18):3418\u201325.","journal-title":"Blood"},{"issue":"10","key":"347_CR7","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cncr.20999","volume":"103","author":"MP Escalon","year":"2005","unstructured":"Escalon MP et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M.D. Anderson Cancer Center experience. Cancer. 2005;103(10):2091\u20138.","journal-title":"Cancer"},{"issue":"3","key":"347_CR8","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2141.2005.05478.x","volume":"129","author":"R Sonnen","year":"2005","unstructured":"Sonnen R et al. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol. 2005;129(3):366\u201372.","journal-title":"Br J Haematol"},{"issue":"5","key":"347_CR9","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/cncr.11610","volume":"98","author":"A Cuttica","year":"2003","unstructured":"Cuttica A et al. Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting: evidence of marked differences in outcome between patients with age-adjusted International Prognostic Index scores 2 and 3. Cancer. 2003;98(5):983\u201392.","journal-title":"Cancer"},{"issue":"12","key":"347_CR10","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","volume":"111","author":"KJ Savage","year":"2008","unstructured":"Savage KJ et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12):5496\u2013504.","journal-title":"Blood"},{"issue":"1","key":"347_CR11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1053\/j.seminhematol.2013.11.003","volume":"51","author":"P Gaulard","year":"2014","unstructured":"Gaulard P, de Leval L. Pathology of peripheral T-cell lymphomas: where do we stand? Semin Hematol. 2014;51(1):5\u201316.","journal-title":"Semin Hematol"},{"issue":"32","key":"347_CR12","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1200\/JCO.2012.42.2345","volume":"30","author":"D Sibon","year":"2012","unstructured":"Sibon D et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte trials. J Clin Oncol. 2012;30(32):3939\u201346.","journal-title":"J Clin Oncol"},{"issue":"1","key":"347_CR13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/j.seminhematol.2013.11.006","volume":"51","author":"NM Reddy","year":"2014","unstructured":"Reddy NM, Evens AM. Chemotherapeutic advancements in peripheral T-cell lymphoma. Semin Hematol. 2014;51(1):17\u201324.","journal-title":"Semin Hematol"},{"issue":"25","key":"347_CR14","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F d\u2019Amore","year":"2012","unstructured":"d\u2019Amore F et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30(25):3093\u20139. The largest prospective study to date which included 160 patients with PTCL of which 115 patients underwent an autologous stem cell transplant. The treatment related mortality was 1.7% and with a median follow-up of 60.5 months the OS was 70%, 52% and 47% for ALCL, AILT and PTCL-NOS, respectively.","journal-title":"J Clin Oncol"},{"issue":"3","key":"347_CR15","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","volume":"104","author":"M Pfreundschuh","year":"2004","unstructured":"Pfreundschuh M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104(3):634\u201341.","journal-title":"Blood"},{"issue":"7","key":"347_CR16","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","volume":"110","author":"A Gallamini","year":"2007","unstructured":"Gallamini A et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood. 2007;110(7):2316\u201323.","journal-title":"Blood"},{"issue":"9","key":"347_CR17","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O\u2019Connor","year":"2011","unstructured":"O\u2019Connor OA et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182\u20139.","journal-title":"J Clin Oncol"},{"issue":"22","key":"347_CR18","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","volume":"117","author":"RL Piekarz","year":"2011","unstructured":"Piekarz RL et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117(22):5827\u201334.","journal-title":"Blood"},{"issue":"19","key":"347_CR19","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes A et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812\u201321.","journal-title":"N Engl J Med"},{"issue":"18","key":"347_CR20","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","volume":"30","author":"B Pro","year":"2012","unstructured":"Pro B et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190\u20136.","journal-title":"J Clin Oncol"},{"issue":"17","key":"347_CR21","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1182\/blood-2013-12-516245","volume":"123","author":"AJ Moskowitz","year":"2014","unstructured":"Moskowitz AJ, Lunning MA, Horwitz SM. How I treat the peripheral T-cell lymphomas. Blood. 2014;123(17):2636\u201344.","journal-title":"Blood"},{"issue":"1","key":"347_CR22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/j.seminhematol.2013.11.001","volume":"51","author":"L Karlin","year":"2014","unstructured":"Karlin L, Coiffier B. The changing landscape of peripheral T-cell lymphoma in the era of novel therapies. Semin Hematol. 2014;51(1):25\u201334.","journal-title":"Semin Hematol"},{"issue":"1","key":"347_CR23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.seminhematol.2013.11.002","volume":"51","author":"P Giulia","year":"2014","unstructured":"Giulia P, Corradini P. Autologous stem cell transplantation for T-cell lymphomas. Semin Hematol. 2014;51(1):59\u201366.","journal-title":"Semin Hematol"},{"issue":"1","key":"347_CR24","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","volume":"27","author":"P Reimer","year":"2009","unstructured":"Reimer P et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27(1):106\u201313. There were 83 patients with PTCL who proceeded to autologous transplant after induction with CHOP. One patient died during high-dose conditioning and the 3-year OS rate was 48% for all patients.","journal-title":"J Clin Oncol"},{"issue":"9","key":"347_CR25","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","volume":"20","author":"P Corradini","year":"2006","unstructured":"Corradini P et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia. 2006;20(9):1533\u20138. This study included 62 patients with PTCL including ALK+ ALCL. The 12-year OS, DFS and event-free survival (EFS) were 34%, 55% and 30%, respectively. The achievement of CR prior to ASCT was associated with an OS benefit.","journal-title":"Leukemia"},{"issue":"1","key":"347_CR26","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0609.2007.00856.x","volume":"79","author":"J Rodriguez","year":"2007","unstructured":"Rodriguez J et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol. 2007;79(1):32\u20138.","journal-title":"Eur J Haematol"},{"issue":"5","key":"347_CR27","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdn022","volume":"19","author":"S Mercadal","year":"2008","unstructured":"Mercadal S et al. Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol. 2008;19(5):958\u201363.","journal-title":"Ann Oncol"},{"issue":"11","key":"347_CR28","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","volume":"25","author":"JS Abramson","year":"2014","unstructured":"Abramson JS et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol. 2014;25(11):2211\u20137. This study described 33 patients who underwent an autologous transplant in first remission. Consolidation with autologous stem cell transplant was associated with an improvement in PFS and OS; however this benefit was lost in multivariate analysis.","journal-title":"Ann Oncol"},{"issue":"12","key":"347_CR29","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/annonc\/mdg459","volume":"14","author":"J Rodriguez","year":"2003","unstructured":"Rodriguez J et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol. 2003;14(12):1768\u201375.","journal-title":"Ann Oncol"},{"issue":"2","key":"347_CR30","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/bmt.2009.165","volume":"45","author":"A Numata","year":"2010","unstructured":"Numata A et al. Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant. 2010;45(2):311\u20136.","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"347_CR31","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbmt.2008.04.004","volume":"14","author":"AI Chen","year":"2008","unstructured":"Chen AI et al. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant. 2008;14(7):741\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"347_CR32","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00277-013-1685-5","volume":"92","author":"JS Ahn","year":"2013","unstructured":"Ahn JS et al. Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial. Ann Hematol. 2013;92(6):789\u201397.","journal-title":"Ann Hematol"},{"issue":"7","key":"347_CR33","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.bmt.1702867","volume":"27","author":"AK Blystad","year":"2001","unstructured":"Blystad AK et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant. 2001;27(7):711\u20136.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"347_CR34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.seminhematol.2013.11.010","volume":"51","author":"N Schmitz","year":"2014","unstructured":"Schmitz N, Wu HS, Glass B. Allogeneic transplantation in T-cell lymphomas. Semin Hematol. 2014;51(1):67\u201372.","journal-title":"Semin Hematol"},{"issue":"11","key":"347_CR35","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","volume":"22","author":"P Corradini","year":"2004","unstructured":"Corradini P et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin\u2019s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol. 2004;22(11):2172\u20136.","journal-title":"J Clin Oncol"},{"issue":"9","key":"347_CR36","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/leu.2014.79","volume":"28","author":"P Corradini","year":"2014","unstructured":"Corradini P et al. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia. 2014;28(9):1885\u201391.","journal-title":"Leukemia"},{"issue":"2","key":"347_CR37","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/annonc\/mdu515","volume":"26","author":"M Loirat","year":"2015","unstructured":"Loirat M et al. Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center. Ann Oncol. 2015;26(2):386\u201392.","journal-title":"Ann Oncol"},{"key":"347_CR38","doi-asserted-by":"crossref","unstructured":"Beitinjaneh A, et al. Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease. Biol Blood Marrow Transplant. 2015;21(5):855\u20139.","DOI":"10.1016\/j.bbmt.2015.01.013"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-015-0347-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-015-0347-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-015-0347-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:34:30Z","timestamp":1559432070000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-015-0347-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,17]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["347"],"URL":"https:\/\/doi.org\/10.1007\/s11864-015-0347-3","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,17]]},"article-number":"34"}}